Phase I Clinical Trial of Vaxinia Oncolytic Virus; “the holy grail of cancer therapeutics”?

CF33-hNIS, a modified vaccinia (small pox) virus will be tested by IV or Intratumoral injection, with or without PD-1 inhibitor, pembrolizumab in patients with advanced or metastaic solid tumors.

Link to Medical News Today Article

Link to Clinical Trial

Link to a Background article

Ancell human PD-1 related Research Products

CD279(PD-1)

CD274 (PD-L1)

CD273 (PD-L2)